Cargando…
Targeting CD47 as a Novel Immunotherapy for Breast Cancer
Nowadays, breast cancer has become the most common cancer worldwide with a high mortality rate. Immune checkpoint blockade holds great promise in tumor‐targeted therapy, and CD47 blockade as one immune therapy is undergoing various preclinical studies and clinical trials to demonstrate its safety an...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289165/ https://www.ncbi.nlm.nih.gov/pubmed/35860564 http://dx.doi.org/10.3389/fonc.2022.924740 |
_version_ | 1784748602947534848 |
---|---|
author | Chen, Can Wang, Runlu Chen, Xi Hou, Yulong Jiang, Jingting |
author_facet | Chen, Can Wang, Runlu Chen, Xi Hou, Yulong Jiang, Jingting |
author_sort | Chen, Can |
collection | PubMed |
description | Nowadays, breast cancer has become the most common cancer worldwide with a high mortality rate. Immune checkpoint blockade holds great promise in tumor‐targeted therapy, and CD47 blockade as one immune therapy is undergoing various preclinical studies and clinical trials to demonstrate its safety and efficacy in breast cancer. In this review, we summarized different therapeutic mechanisms targeting CD47 and its prognostic role and therapeutic value in breast cancer. |
format | Online Article Text |
id | pubmed-9289165 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92891652022-07-19 Targeting CD47 as a Novel Immunotherapy for Breast Cancer Chen, Can Wang, Runlu Chen, Xi Hou, Yulong Jiang, Jingting Front Oncol Oncology Nowadays, breast cancer has become the most common cancer worldwide with a high mortality rate. Immune checkpoint blockade holds great promise in tumor‐targeted therapy, and CD47 blockade as one immune therapy is undergoing various preclinical studies and clinical trials to demonstrate its safety and efficacy in breast cancer. In this review, we summarized different therapeutic mechanisms targeting CD47 and its prognostic role and therapeutic value in breast cancer. Frontiers Media S.A. 2022-07-04 /pmc/articles/PMC9289165/ /pubmed/35860564 http://dx.doi.org/10.3389/fonc.2022.924740 Text en Copyright © 2022 Chen, Wang, Chen, Hou and Jiang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Chen, Can Wang, Runlu Chen, Xi Hou, Yulong Jiang, Jingting Targeting CD47 as a Novel Immunotherapy for Breast Cancer |
title | Targeting CD47 as a Novel Immunotherapy for Breast Cancer |
title_full | Targeting CD47 as a Novel Immunotherapy for Breast Cancer |
title_fullStr | Targeting CD47 as a Novel Immunotherapy for Breast Cancer |
title_full_unstemmed | Targeting CD47 as a Novel Immunotherapy for Breast Cancer |
title_short | Targeting CD47 as a Novel Immunotherapy for Breast Cancer |
title_sort | targeting cd47 as a novel immunotherapy for breast cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289165/ https://www.ncbi.nlm.nih.gov/pubmed/35860564 http://dx.doi.org/10.3389/fonc.2022.924740 |
work_keys_str_mv | AT chencan targetingcd47asanovelimmunotherapyforbreastcancer AT wangrunlu targetingcd47asanovelimmunotherapyforbreastcancer AT chenxi targetingcd47asanovelimmunotherapyforbreastcancer AT houyulong targetingcd47asanovelimmunotherapyforbreastcancer AT jiangjingting targetingcd47asanovelimmunotherapyforbreastcancer |